Malaria remains a significant public health concern, particularly in sub-Saharan Africa, where the majority of cases and fatalities occur, especially among children under five. Although there was a significant decline in global mortality and incidence between 2000 and 2015, progress has stalled sinc...e the late 2010s due to climate change, conflict, drug and insecticide resistance, and the ongoing effects of the pandemic. Economic modelling shows that achieving the Sustainable Development Goal target of reducing malaria incidence by 90% by 2030 could generate substantial economic benefits, including an increase in GDP of $142.7 billion in endemic countries and $80.7 billion in global trade gains. To save lives, strengthen health systems, and drive sustainable economic growth, renewed investments in malaria control and elimination programmes, vaccine deployment, and coordinated international support are essential.
Accessed on 25/08/2025.
more
Découverte par Alphonse Laveran en 1880, cette maladie parasitaire demeure en 2022 l’endémie la plus répandue dans les régions tropicales et subtropicales. Selon le rapport mondial sur le paludisme de 2021 de l'OMS, on estime à 232 millions le nombre de cas en 2019 dans 87 pays endémiques, d...ont 94 % sont concentrés en Afrique subsaharienne et sont principalement dus à Plasmodium falciparum. Le nombre de décès est passé de 897 000 en 2000 à 568 000 en 2019, dont près de 95 % sont survenus dans 31 pays. Des baisses marquées sont également observées en Asie du Sud-Est. Avec des financements suffisants et un renforcement des campagnes d'information, le contrôle, voire l'éradication du paludisme, restent envisageables.
more
Malaria and HIV, two of the world’s most deadly diseases, are widespread, but their distribution overlaps greatly in sub-Saharan Africa. Consequently, malaria and HIV coinfection (MHC) is common in the region. In this paper, pertinent publications on the prevalence, impact, and treatment strategie...s of MHC obtained by searching major electronic databases (PubMed, PubMed Central, Google Scholar, ScienceDirect, and Scopus) were reviewed, and it was found that the prevalence of MHC in SSA was 0.7%–47.5% overall. Prevalence was 0.7%–47.5% in nonpregnant adults, 1.2%–27.8% in children, and 0.94%–37% in pregnant women. MHC was associated with an increased frequency of clinical parasitemia and severe malaria, increased parasite and viral load, and impaired immunity to malaria in nonpregnant adults, children, and pregnant women, increased in placental malaria and related outcomes in pregnant women, and impaired antimalarial drug efficacy in nonpregnant adults and pregnant women. Although a few cases of adverse events have been reported in coinfected patients receiving antimalarial and antiretroviral drugs concurrently, available data are very limited and have not prompted major revision in treatment guidelines for both diseases. Artemisinin-based combination therapy and cotrimoxazole are currently the recommended drugs for treatment and prevention of malaria in HIV-infected children and adults. However, concurrent administration of cotrimoxazole and sulfadoxine–pyrimethamine in HIV-infected pregnant women is not recommended, because of high risk of sulfonamide toxicity. Further research is needed to enhance our understanding of the impact of malaria on HIV, drug–drug interactions in patients receiving antimalarials and antiretroviral drugs concomitantly, and the development of newer, safer, and more cost-effective drugs and vaccines to prevent malaria in HIV-infected pregnant women.
more
This document, issued by the United Nations Medical Directors in July 2021, outlines vaccination and malaria prophylaxis recommendations for UN personnel travelling on official business and UN healthcare workers. The guidance aims to minimise the risk of vaccine-preventable diseases and malaria by f...ocusing on three key areas:(1) routine vaccines, such as those for influenza, measles, polio, hepatitis B, varicella and SARS-CoV-2 (the virus that causes the disease known as 'Covid-19'), which are recommended for all staff regardless of their destination;
(2) destination-based measures, including mandatory vaccines (e.g. yellow fever, meningitis and polio), recommended vaccines depending on regional risks (e.g. cholera, typhoid, hepatitis A and rabies) and WHO-advised malaria prevention through mosquito protection and chemoprophylaxis. The third area covers vaccines for healthcare workers with direct patient or laboratory exposure, including hepatitis B, influenza, diphtheria, pertussis and others. The recommendations emphasise the importance of pre-travel medical consultations, adherence to host country requirements, and individualised risk assessments.
more
The poster is a public health communication tool designed to prevent the transmission of diseases such as chikungunya, dengue and Zika. The poster emphasises that Aedes mosquitoes bite aggressively during the day and sometimes at night, and recommends the key prevention strategies.
Accessed on 27.../08/2025.
more
Early Adolescent Skills for Emotions (EASE) is an evidence-based group psychological intervention to help 10–15-year-olds affected by internalizing problems (e.g. stress and symptoms of anxiety, depression) in communities exposed to adversity. Published by the World Health Organization (WHO) and U...nited Nations Children’s Fund (UNICEF), EASE aims to support adolescents and their caregivers with skills to reduce distress. The EASE training manual accompanies the EASE intervention manual and is designed to be used to train EASE helpers (those who deliver the EASE intervention to adolescents and caregivers) and EASE trainers/supervisors (those who will go on to train/supervise future EASE helpers).
more
In line with the Defeating meningitis by 2030: a global road map, the WHO guidelines on meningitis diagnosis, treatment and care Executive Summary provides a summary of the evidence-based recommendations for the clinical management of children and adults with community-acquired meningitis, including... acute and long-term care. Meningitis poses a significant public health threat, despite successful efforts to control the disease globally. The burden of morbidity and mortality from meningitis remains high, particularly in low- and middle-income countries and in settings experiencing large-scale, disruptive epidemics.
more
The objective of this guideline is to present the complete set of all WHO recommendations and best practice statements relating to abortion. While legal, regulatory, policy and service-delivery contexts may vary from country to country, the recommendations and best practices described in this docume...nt aim to enable evidence-based decision-making with respect to quality abortion care.
more
This publication provides an overview of evidence and guidance on the growing challenge of workplace heat stress in the context of climate change. It highlights the health and productivity risks faced by billions of workers, especially in manual labor sectors. The report details the physiological, s...ocioeconomic, and mental health impacts of heat stress and outlines evidence-based strategies for prevention and mitigation. It emphasizes the need for occupational heat action programmes, stakeholder collaboration, and tailored interventions to protect vulnerable workers, reduce productivity losses, and support sustainable development in a warming world.
more
The brief on key findings from the 2025 edition of the WHO anaemia estimates provides a snapshot of the current status of anaemia among women aged 15–49 years at the country, regional, and global levels, along with progress toward achieving the global anaemia target by 2030, in alignment with the ...Sustainable Development Goals.
more
Published by the World Health Organization, International Travel and Health 2012 provides comprehensive guidance on the health risks associated with international travel, as well as practical measures to prevent or reduce adverse health outcomes. Although the book is primarily intended for medical a...nd public health professionals who advise travellers, it is also useful for travel agents, transport providers and informed travellers. It covers a variety of topics, such as preventing infectious diseases, environmental hazards, accident risks, vaccination requirements, malaria prophylaxis and travel medical kits. Particular attention is given to travellers visiting friends and relatives, those travelling at short notice, and those journeying to remote or high-risk destinations. Recommendations are based on individual health status, destination, travel duration and behaviour. The publication emphasises the shared responsibility of travellers, healthcare providers and the travel industry in promoting safe travel and minimising preventable illnesses. Online updates provide real-time information on outbreaks, vaccine guidance and disease distribution.
more
This document provides an overview of malaria rapid diagnostic tests (RDTs) for Principal Recipients (PRs) of Global Fund grants, indicating their eligibility for procurement under the Global Fund's Quality Assurance Policy. The included products have been assessed and approved by the WHO Prequalifi...cation of Diagnostics Programme (WHO PQ), the relevant regulatory authorities of the GHTF founding members or the Global Fund Expert Review Panel for Diagnostics (ERPD). Updates are made based on new evidence and regulatory assessments.
more
The 2022 report reviews the global malaria diagnostics market and technological landscape to support Unitaid’s 2023–2027 strategy for quality malaria case management. The report highlights the stalled progress of malaria control efforts, the gaps in access to diagnostics and the public health im...plications of P. falciparum HRP2/3 gene deletions, which compromise the accuracy of the widely used HRP2-detecting rapid diagnostic tests (RDTs). The report analyses the malaria RDT market, noting supplier diversification, price trends and production shifts resulting from the pandemic. It also addresses the emerging point-of-care G6PD testing market, which is required to ensure the safe radical cure of P. vivax infections. It surveys technological innovation, including digital microscopy, hemozoin tests, nucleic acid detection and biosensors, while emphasising that RDTs and microscopy will remain the mainstay of case management in the near term. The report identifies market shortcomings, access barriers and opportunities to improve malaria case management and diagnostic coverage.
more
This document provides technical guidance for manufacturers seeking World Health Organization (WHO) prequalification of in vitro diagnostic devices (IVDs) for malaria, with a focus on rapid diagnostic tests (RDTs) for symptomatic patients. It summarises the minimum performance requirements, includin...g analytical and clinical performance standards, and emphasises considerations relating to diverse specimen types, testing environments and user populations in low- and middle-income countries. The guidance is aligned with the criteria and prequalification processes of the WHO Global Malaria Programme, while clarifying that demonstration of clinical utility is outside the scope of prequalification.
more
Antimalarial chemotherapy is crucial for reducing morbidity, mortality, and drug resistance, and is the cornerstone of malaria control. Existing antimalarial drugs act at different stages of the parasite’s life cycle. These drugs range from classic agents such as chloroquine and quinine to newer a...rtemisinin derivatives. They include tissue schizonticides, blood schizonticides, gametocytocides, and sporontocides. Artemisinin and its derivatives are the most effective and fastest-acting treatment against drug-resistant Plasmodium falciparum, achieving rapid parasite clearance and reducing transmission potential. Other key drugs include mefloquine, halofantrine, proguanil, sulfadoxine–pyrimethamine, atovaquone–proguanil, tetracyclines, clindamycin and azithromycin. Each of these drugs has a specific mechanism of action, pharmacokinetics, efficacy, safety profile and contraindications. Rational drug combinations and adherence to national treatment guidelines are essential for managing resistance, ensuring safety in vulnerable populations such as children and pregnant women, and optimising therapeutic outcomes in cases of both uncomplicated and severe malaria.
more
Combination therapy is a cornerstone of modern malaria treatment, particularly in the context of widespread multidrug resistance. Using two or more antimalarial drugs with different mechanisms simultaneously enhances efficacy, shortens treatment duration, improves compliance and delays the developme...nt of resistance. Artemisinin-based combination therapies (ACTs), such as artemether–lumefantrine, artesunate–amodiaquine and artesunate–sulfadoxine/pyrimethamine, are highly effective in rapidly clearing parasites and reducing gametocyte carriage. They are also generally well tolerated. Non-artemisinin combinations, quinine-based regimens and novel combinations (e.g. piperaquine–dihydroartemisinin) offer alternative therapeutic options, although clinical experience with these remains limited. Although ACTs are the preferred first-line treatment, factors such as cost, local drug resistance patterns, safety during pregnancy and paediatric use must inform implementation and policy decisions.
more
To mark the International Day of the African Child, Medicines for Malaria Venture (MMV) celebrated the inclusion of three of its antimalarial medicines on the WHO Model List of Essential Medicines (EML) and the EML for Children (EMLc). These are two artemisinin-based combination therapies (ACTs) for... adults, children and infants, and a rectal artesunate formulation for the pre-referral treatment of severe malaria in young children. The approved therapies — pyronaridine–artesunate, dihydroartemisinin–piperaquine and rectal artesunate — offer child-friendly formulations and are the first-line treatment for uncomplicated malaria caused by Plasmodium falciparum and P. vivax. Inclusion in the EMLc facilitates national adoption, improves access to high-quality treatments and addresses the disproportionate malaria burden among children under five. This supports global efforts to reduce malaria mortality and advance elimination.
more
This document provides technical guidance for manufacturers seeking World Health Organization (WHO) prequalification of in vitro diagnostic devices (IVDs) for malaria, with a focus on rapid diagnostic tests (RDTs) for symptomatic patients. It summarises the minimum performance requirements, includin...g analytical and clinical performance standards, and emphasises considerations relating to diverse specimen types, testing environments and user populations in low- and middle-income countries. The guidance is aligned with the criteria and prequalification processes of the WHO Global Malaria Programme, while clarifying that demonstration of clinical utility is outside the scope of prequalification.
more
Malaria remains a significant public health concern in the SADC region, accounting for 20% of childhood deaths, as well as prompting numerous outpatient visits and hospitalisations. Around three-quarters of the population, including 35 million children under the age of five and 8.5 million pregnant ...women, are at risk. Transmission patterns vary from high and stable in the north to malaria-free in the south, with low, unstable and seasonal zones in between. Although interventions such as indoor residual spraying (IRS), insecticide-treated nets (ITNs/LLINs), intermittent preventive treatment in pregnancy (IPTp), rapid diagnostic tests (RDTs), and artemisinin-based combination therapies (ACTs) have reduced the malaria burden, challenges persist in terms of funding, human resources, surveillance, and cross-border coordination. Achieving malaria elimination in the SADC region requires harmonised regional standards, strengthened surveillance, and improved access to quality treatment and policy prioritisation.
Accessed on 27/08/2025.
more
The 2024 World Malaria Report shows that the malaria burden remains overwhelmingly concentrated in Africa. The continent accounted for 94% of global cases and 95% of malaria-related deaths in 2023. Although the number of malaria cases increased globally from 204 million in 2000 to 246 million in 202...3, the number of deaths declined from 805,000 to 569,000. Children under five are still the most affected group, accounting for 76% of malaria deaths in Africa. A few countries, particularly Nigeria and the Democratic Republic of the Congo, carry the highest burden. Since 2000, Africa has significantly reduced malaria incidence and mortality, averting over 1.7 billion cases and 12 million deaths. Nevertheless, malaria continues to pose a significant health challenge, necessitating ongoing action and investment.
more